Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants [Phase 3]

View source ↗

Summary

Phase 3 trial results for TMC435 in treatment-naive genotype 1 hepatitis C patients, assessing efficacy, safety, and tolerability, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2014-06-13